Geng Sun , Hai-Qian Zhao , Yuan-Yuan Huang , Zhan-Ying Guo , Lin Zhang , Hao Zhu , Xin-Yue Wang , Hao-Nan Ye , Cai-Ping Chen
{"title":"Adiponectin receptor agonist adipoRon alleviates imiquimod-induced murine psoriasis","authors":"Geng Sun , Hai-Qian Zhao , Yuan-Yuan Huang , Zhan-Ying Guo , Lin Zhang , Hao Zhu , Xin-Yue Wang , Hao-Nan Ye , Cai-Ping Chen","doi":"10.1016/j.intimp.2025.114568","DOIUrl":null,"url":null,"abstract":"<div><div>Psoriasis is a chronic inflammatory skin disease involving inflammation, immune responses and keratinocytes proliferation. It has been suggested that adiponectin/adiponectin receptor 1 (AdipoR1) signaling plays a role in regulating psoriatic skin inflammation. AdipoRon is a small molecule agonist of AdipoR1 and AdipoR2. The effect of adipoRon on psoriasis has not been elucidated. In this study, using a GEO database, we found that the expression of adiponectin was substantially decreased in skin lesions of psoriasis patients. This reduction was also validated in an imiquimod-induced psoriasis mouse model. Interestingly, we found that topical administration of adipoRon significantly ameliorated skin lesions induced by imiquimod. The critical pro-inflammatory cytokines (IL-6, IL-17A and IL-23) and the infiltration of macrophages, especially M1 macrophages were dramatically decreased while the infiltration of M2 macrophages were slightly increased in the skin lesions upon adipoRon treatment. Mechanistically, adipoRon inhibited macrophage inflammation and keratinocytes proliferation <em>via</em> activation of AMPK signaling pathway. Collectively, our study demonstrates that adipoRon displayed anti-inflammatory activity and anti-proliferation of keratinocytes, and attenuated psoriatic response. Activating AdipoR1 signaling pathway by adipoRon or others may represent a novel therapeutic approach to psoriasis.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"154 ","pages":"Article 114568"},"PeriodicalIF":4.8000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576925005582","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Psoriasis is a chronic inflammatory skin disease involving inflammation, immune responses and keratinocytes proliferation. It has been suggested that adiponectin/adiponectin receptor 1 (AdipoR1) signaling plays a role in regulating psoriatic skin inflammation. AdipoRon is a small molecule agonist of AdipoR1 and AdipoR2. The effect of adipoRon on psoriasis has not been elucidated. In this study, using a GEO database, we found that the expression of adiponectin was substantially decreased in skin lesions of psoriasis patients. This reduction was also validated in an imiquimod-induced psoriasis mouse model. Interestingly, we found that topical administration of adipoRon significantly ameliorated skin lesions induced by imiquimod. The critical pro-inflammatory cytokines (IL-6, IL-17A and IL-23) and the infiltration of macrophages, especially M1 macrophages were dramatically decreased while the infiltration of M2 macrophages were slightly increased in the skin lesions upon adipoRon treatment. Mechanistically, adipoRon inhibited macrophage inflammation and keratinocytes proliferation via activation of AMPK signaling pathway. Collectively, our study demonstrates that adipoRon displayed anti-inflammatory activity and anti-proliferation of keratinocytes, and attenuated psoriatic response. Activating AdipoR1 signaling pathway by adipoRon or others may represent a novel therapeutic approach to psoriasis.
期刊介绍:
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.
The subject material appropriate for submission includes:
• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
• Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
• Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.
• Agents that activate genes or modify transcription and translation within the immune response.
• Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
• Production, function and regulation of cytokines and their receptors.
• Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.